AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
208.16
+1.56 (0.76%)
At close: May 4, 2026, 4:00 PM EDT
208.01
-0.15 (-0.07%)
After-hours: May 4, 2026, 7:57 PM EDT
AbbVie Revenue
AbbVie had revenue of $15.00B in the quarter ending March 31, 2026, with 12.43% growth. This brings the company's revenue in the last twelve months to $62.82B, up 9.50% year-over-year. In the year 2025, AbbVie had annual revenue of $61.16B with 8.57% growth.
Revenue (ttm)
$62.82B
Revenue Growth
+9.50%
P/S Ratio
5.86
Revenue / Employee
$1,102,088
Employees
57,000
Market Cap
368.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.16B | 4.83B | 8.57% |
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
| Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
| Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
| Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
| Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
| Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
| Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
| Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
| Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
| Dec 31, 2010 | 15.64B | 1.42B | 10.02% |
| Dec 31, 2009 | 14.21B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Eli Lilly and Company | 72.25B |
| Merck & Co. | 65.77B |
| Pfizer | 62.58B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 48.59B |
ABBV News
- 3 days ago - Big Pharma M&A set for mega year as patent expiries drive deal urgency - Reuters
- 4 days ago - AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec - GlobeNewsWire
- 4 days ago - Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month - PRNewsWire
- 5 days ago - AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength - Benzinga
- 5 days ago - AbbVie Earnings Call Transcript: Q1 2026 - Transcripts
- 5 days ago - AbbVie Raises FY Guidance on Immunology, Neuroscience Growth - WSJ
- 5 days ago - AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline - Reuters
- 5 days ago - AbbVie Reports First-Quarter 2026 Financial Results - PRNewsWire